Developing new generation medicines for Central Nervous System (CNS) diseases and disorders with high unmet need
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new CNS medicines with rapid onset therapeutic activity and without the psychological and other side effects and safety concerns that often limit the clinical utility of current treatments for major depressive disorder, neuropathic pain, social anxiety disorder and suicidal ideation.
Our Pipeline